Validation of new biomarkers in systemic autoimmune diseases

Nature Reviews Rheumatology

Volumn 7, Issue 12, 2011, Pages 708-717

  Tektonidou, Maria G ^a   Ward, Michael M ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL CROSSLINKED TELOPEPTIDE OF TYPE II COLLAGEN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; COMPLEMENT COMPONENT C4D; INTERFERON; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCALCITONIN; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VALIDATION STUDY;

AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; PROGNOSIS; VALIDATION STUDIES AS TOPIC;

EID: 82955162554     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.157     Document Type: Review

References (71)

1. Atkinson, A. J. Jr et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
2. Muñoz, A. & Gange, S. J. Methodological issues for biomarkers and intermediate outcomes in cohort studies. Epidemiol. Rev. 20, 29-42 (1998). (Pubitemid 28449751)
3. Illei, G. G., Tackey, E., Lapteva, L. & Lipsky, P. E. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 50, 1709-1720 (2004). (Pubitemid 38725082)
4. Ward, M. M. Evaluative laboratory testing. Assessing tests that assess disease activity. Arthritis Rheum. 38, 1555-1563 (1995).
5. Tektonidou, M. G. & Ward, M. M. Validity of clinical associations of biomarkers in translational research studies: The case of systemic autoimmune diseases. Arthritis Res. Ther. 12, R179 (2010).
6. Sackett, D. L. & Haynes, R. B. The architecture of diagnostic research. BMJ 324, 539-541 (2002).
7. Baroni, S. S. et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354, 2667-2676 (2006).
8. Gabrielli, A. et al. Stimulatory autoantibodies to the PDGF receptor: A link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun. Rev. 7, 121-126 (2007). (Pubitemid 350116724)
9. Svegliati, S. et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110, 237-241 (2007). (Pubitemid 47026840)
10. Classen, J. F. et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum. 60, 1137-1144 (2009).
11. Loizos, N. et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor a in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum. 60, 1145-1151 (2009).
12. Gabrielli, A., Moroncini, G., Svegliati, S. & Avvedimento, E. V. Autoantibodies against the platelet-derived growth factor receptor in scleroderma: Comment on the articles by Classen et al. and Loizos et al. Arthritis Rheum. 60, 3521-3522 (2009).
13. Balada, E. et al. Anti-PDGFR-A antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann. Rheum. Dis. 67, 1027-1029 (2008). (Pubitemid 351956668)
14. Kurasawa, K. et al. Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus. Mod. Rheumatol. 20, 458-465 (2010).
15. Becker, K. L., Nylén, E. S., White, J. C., Müller, B. & Snider, R. H. Jr. Clinical review 167: Procalcitonin and the calcitonin gene family in inflammation, infection, and sepsis: A journey from calcitonin back to its precursors. J. Clin. Endocrinol. Metab. 89, 1512-1525 (2004). (Pubitemid 38507896)
16. Simon, L., Gauvin, F., Amre, D. K., Saint-Louis, P. & Lacroix, J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-Analysis. Clin. Infect. Dis. 39, 206-217 (2004). (Pubitemid 38971491)
17. Tang, B. M., Eslick, G. D., Craig, J. C. & McLean, A. S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-Analysis. Lancet Infect. Dis. 7, 210-217 (2007). (Pubitemid 46274517)
18. Eberhard, O. K. et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-Associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 40, 1250-1256 (1997). (Pubitemid 27430136)
19. Shin, K. C. et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann. Rheum. Dis. 60, 988-989 (2001). (Pubitemid 32885681)
20. Lanoix, J. P. et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 20, 125-130 (2011).
21. Moosig, F., Csernok, E., Reinhold-Keller, E., Schmitt, W. & Gross, W. L. Elevated procalcitonin levels in active Wegener's granulomatosis. J. Rheumatol. 25, 1531-1533 (1998). (Pubitemid 28364758)
22. Schwenger, V., Sis, J., Breitbart, A. & Andrassy, K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 26, 274-276 (1998). (Pubitemid 28466499)
23. Zycinska, K., Wardyn, K. A., Zielonka, T. M., Tyszko, P. & Straburzynski, M. Procalcitonin as an indicator of systemic response to infection in active pulmonary Wegener's granulomatosis. J. Physiol. Pharmacol. 59 (Suppl. 6), 839-844 (2008).
24. Tamaki, K. et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J. Rheumatol. 35, 114-119 (2008).
25. Scirè, C. A. et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin. Exp. Rheumatol. 24, 123-128 (2006). (Pubitemid 43826859)
26. Chen, D. Y. et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still's disease. Ann. Rheum. Dis. 68, 1074-1075 (2009).
27. Griffiths, B., Mosca, M. & Gordon, C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract. Res. Clin. Rheumatol. 19, 685-708 (2005). (Pubitemid 41258578)
28. Liu, C. C. & Ahearn, J. M. The search for lupus biomarkers. Best Pract. Res. Clin. Rheumatol. 23, 507-523 (2009).
29. Kirou, K. A. et al. Coordinate overexpression of interferon-A-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50, 3958-3967 (2004). (Pubitemid 39643944)
30. Baechler, E. C., Gregersen, P. K. & Behrens, T. W. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16, 801-807 (2004). (Pubitemid 39423672)
31. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003). (Pubitemid 36297546)
32. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003). (Pubitemid 36350866)
33. Kirou, K. A. et al. Activation of the interferon-A pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491-1503 (2005). (Pubitemid 40663941)
34. Feng, X. et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2951-2962 (2006). (Pubitemid 44497776)
35. Nikpour, M., Dempsey, A. A., Urowitz, M. B., Gladman, D. D. & Barnes, D. A. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1069-1075 (2008).
36. Landolt-Marticorena, C. et al. Lack of association between the interferon-A signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 68, 1440-1446 (2009).
37. Kaneko H. et al. Circulating levels of beta-chemokines in systemic lupus erythematosus. J. Rheumatol. 26, 568-573 (1999). (Pubitemid 29125573)
38. Lit, L. C., Wong, C. K., Tam, L. S., Li, E. K. & Lam, C. W. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 65, 209-215 (2006). (Pubitemid 43131995)
39. Fu, Q. et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res. Ther. 10, R112 (2008).
40. Narumi, S., Takeuchi, T., Kobayashi, Y. & Konishi, K. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12, 1561-1565 (2000).
41. Bauer, J. W. et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 3, e491 (2006).
42. Vilá, L. M. et al. Association of serum MIP-1a, MIP-1ß, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin. Rheumatol. 26, 718-722 (2007). (Pubitemid 46554079)
43. Bauer, J. W. et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum. 60, 3098-3107 (2009).
44. Buyon, J. P., Tamerius, J., Belmont, H. M. & Abramson, S. B. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum. 35, 1028-1037 (1992).
45. Calano, S. J. et al. Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers. Adv. Exp. Med. Biol. 586, 381-390 (2006).
46. Manzi, S., Ahearn, J. M. & Salmon, J. New insights into complement: A mediator of injury and marker of disease activity in systemic lupus erythematosus. Lupus 13, 298-303 (2004). (Pubitemid 38788486)
47. Manzi, S. et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum. 50, 3596-3604 (2004). (Pubitemid 39488685)
48. Singh, V., Mahoney, J. A. & Petri, M. Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. J. Rheumatol. 35, 1989-1993 (2008).
49. Yang, D. H., Chang, D. M., Lai, J. H., Lin, F. H. & Chen, C. H. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford) 48, 1083-1087 (2009).
50. Kao, A. H. et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum. 62, 837-844 (2010).
51. Liu, C. C. et al. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus. Arthritis Rheum. 52, 3087-3099 (2005).
52. Navratil, J. S. et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum. 54, 670-674 (2006). (Pubitemid 43228646)
53. Garnero, P. Biomarkers for osteoporosis management: Utility in diagnosis, fracture risk prediction, and therapy monitoring. Mol. Diagn. Ther. 12, 157-170 (2008). (Pubitemid 351754589)
54. Garnero, P., Rousseau, J. C. & Delmas, P. D. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 43, 953-968 (2000). (Pubitemid 30368171)
55. Garnero, P., Jouvenne, P., Buchs, N., Delmas, P. D. & Miossec, P. Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: Assessment with serum type I collagen breakdown products. Bone 24, 381-385 (1999). (Pubitemid 29134976)
56. Garnero, P. et al. Association of baseline levels of markers of bone and cartilage degradation with long-term prognosis of joint damage in patients with early arthritis. The COBRA study. Arthritis Rheum. 46, 2847-2856 (2002). (Pubitemid 35315875)
57. Landewé, R. et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum. 50, 1390-1399 (2004). (Pubitemid 38608060)
58. Jansen, L. M. et al. Serological bone markers and joint damage in early polyarthritis. J. Rheumatol. 31, 1491-1496 (2004). (Pubitemid 39006628)
59. Forsblad d'Elia, H. et al. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: A randomized controlled trial [ISRCTN46523456]. Arthritis Res. Ther. 6, R457-R468 (2004).
60. Syversen, S. W. et al. Cartilage and bone biomarkers in rheumatoid arthritis: Prediction of 10-year radiographic progression. J. Rheumatol. 36, 266-272 (2009).
61. Wislowska, M., Jakubicz, D., Stepien, K. & Cicha, M. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol. Int. 29, 1403-1409 (2009).
62. van Tuyl, L. H. et al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann. Rheum. Dis. 69, 1623-1628 (2010).
63. Christgau, S. et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29, 209-215 (2001). (Pubitemid 32823562)
64. Garnero, P., Gineyts, E., Christgau, S., Finck, B. & Delmas, P. D. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum. 46, 21-30 (2002). (Pubitemid 34121647)
65. Young-Min, S. et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared to traditional markers. Arthritis Rheum. 56, 3236-3247 (2007). (Pubitemid 47585418)
66. Marotte, H., Gineyts, E., Miossec, P. & Delmas, P. D. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann. Rheum. Dis. 68, 1197-1200 (2009).
67. Hashimoto, J. et al. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod. Rheumatol. 19, 273-282 (2009).
68. Christensen, A. F. et al. Differential association of the N-propeptide of collagen IIA (PIIANP) and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis. Clin. Exp. Rheumatol. 27, 307-314 (2009).
69. Christensen, A. F. et al. Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides. J. Rheumatol. 37, 1113-1120 (2010).
70. Maksymowych, W. P. et al. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: The OMERACT 9 v2 criteria. J. Rheumatol. 36, 1785-1791 (2009).
71. Maksymowych, W. P. et al. Proposal for levels of evidence scheme for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J. Rheumatol. 36, 1792-1799 (2009).